US Stock Movement | Novo Nordisk (NVO.US) drops over 8% as $23 billion daily capital market target falls short of expectations

Zhitong Finance APP has learned that on Monday, Novo Nordisk (NVO.US) opened lower and continued to decline, falling by more than 8% as of press time. According to reports, on September 21, Novo Nordisk held a "Capital Markets Day" (CMD) in London, pledging to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in additional sales revenue. However, its $23 billion target appears to be below market expectations. Over the past year, the company has laid off 13,000 employees to continuously reduce costs. Whether its core pipeline drug CagriSema can ultimately realize its commercial value, and whether a new growth trajectory can be established, remain key focuses for the capital markets going forward.